#USA #Pleasanton #Type 2 Diabetes #Aqua Medical #Bob Haggerty

Introduction

Aqua Medical, Inc., a groundbreaking clinical-stage medical device company based in Pleasanton, California, has recently made a significant leadership change by appointing Bob Haggerty as its new President and Chief Executive Officer. This strategic move comes at a crucial time as the company begins clinical trials for its innovative treatment targeting type 2 diabetes using minimally invasive endoscopic therapies. Haggerty takes over from Lloyd Mencinger, who has successfully led the organization for the past nine years.

Bob Haggerty's Expertise

Bringing over 35 years of experience in the medical device industry, Haggerty is recognized for his extensive background in gastroenterology and various leadership roles at prominent firms such as Boston Scientific and Covidien (now part of Medtronic). During his tenure at BÂRRX Medical, he pioneered the commercialization of radiofrequency ablation technologies, culminating in substantial revenue growth and a successful acquisition by Covidien. Haggerty’s proven track record of introducing transformative medical technologies positions him aptly to lead Aqua Medical’s ambitious projects.

A Pivotal Moment in Treatment

Recently, Aqua Medical treated its first patient in the U.S. for type 2 diabetes within an Investigational Device Exemption (IDE) pilot study. Conducted at UNC Health in Chapel Hill, North Carolina, this study represents a landmark moment for Aqua Medical as it seeks to evaluate its Proximal Intestinal Mucosal Ablation (PIMA) procedure. Data from previous trials conducted outside the U.S. have shown promising results, indicating that the PIMA procedure could drastically alter treatment pathways for diabetes patients.

Addressing a Major Health Crisis

Type 2 diabetes is a significant global health challenge, affecting an estimated 35 million individuals in the United States alone and nearly 500 million worldwide. This condition imposes tremendous healthcare costs and complicates the lives of those afflicted. The need for effective, novel treatments has never been greater, and Aqua Medical's pioneering approach aims to bridge the gap for patients whose existing options have proven ineffective.

Community Support and Strategic Vision

According to Greg Barrett, Chairman of Aqua Medical's Board, Haggerty’s depth of experience and established connections within the gastroenterology community will be invaluable as Aqua embarks on this critical clinical phase. Haggerty echoes this sentiment, expressing excitement about the potential to transform diabetes care with the company’s electric approach. "My career has been dedicated to advancing gastrointestinal technologies," stated Haggerty during his introduction as CEO. He emphasized Aqua’s initiative as one of the most impressive opportunities in the healthcare sector today.

The Market Potential

The market for treatments addressing type 2 diabetes is vast, with estimates indicating an opportunity ranging from $4.5 billion to $6 billion within the U.S. alone. Aqua Medical stands out among its competitors, being one of the only two companies globally focusing on duodenal mucosal resurfacing (DMR) as a direct intervention for diabetes. Its targeted technique aims to provide outpatient solutions devoid of lengthy hospital stays or complex procedures.

Conclusion

As Aqua Medical embarks on this new chapter under Haggerty's stewardship, the company is poised to make a significant impact on the management of type 2 diabetes. With its commitment to developing groundbreaking therapies and the support of experienced leadership, Aqua Medical is ready to take on the challenges of diabetes treatment and improve the lives of millions around the globe.

For more information about Aqua Medical and its innovative therapies, visit www.aquaendoscopy.com.